---
title: "Sprint Bioscience Q2 FY26 operating loss widens to SEK 16.6 million; net sales show no revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296990638.md"
description: "Sprint Bioscience reported a widened Q2 FY26 operating loss of SEK 16.6 million, up from SEK 6.8 million in the prior year, with net sales dropping to nil. The first-half operating loss reached SEK 30.9 million. However, cash and equivalents increased to SEK 93.3 million. The company also signed a deal with Lilly TuneLab, citing strong partnering interest in oncology, immunology, and inflammation."
datetime: "2026-08-26T05:31:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296990638.md)
  - [en](https://longbridge.com/en/news/296990638.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296990638.md)
generator: "portal-rs"
---

# Sprint Bioscience Q2 FY26 operating loss widens to SEK 16.6 million; net sales show no revenue

-   Sprint Bioscience posted a wider Q2 operating loss of SEK 16.6 million, deteriorating from SEK 6.8 million a year earlier. \* Net sales were nil, down from SEK 13.9 million in the year-ago quarter; operating cash flow was SEK -14.6 million. \* H1 operating loss widened to SEK 30.9 million from SEK 11.8 million, while operating cash flow fell to SEK -33 million. \* Cash and cash equivalents rose to SEK 93.3 million versus SEK 24.7 million at end-June 2025. \* Signed a deal with Lilly TuneLab; CEO Johan Emilsson cited strong partnering interest around oncology, immunology and inflammation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sprint Bioscience AB published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)

## Related News & Research

- [BioArctic Q2 FY26 turns to net loss of SEK 11.2 million; revenue falls to SEK 247.5 million](https://longbridge.com/en/news/296992922.md)
- [Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs](https://longbridge.com/en/news/297082109.md)
- [Lilly's Cost-Saving Study Leaves Out Zepbound's Price](https://longbridge.com/en/news/297077502.md)
- [02:46 ETBioArctic: Interim Report for the period April - June 2026](https://longbridge.com/en/news/296997614.md)
- [How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story](https://longbridge.com/en/news/296430987.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**